WASHINGTON, DC, April 27, 2017 (Newswire.com) - Kinexum, a distinguished resource for research, development and commercialization of life science products, today announces the appointment of Thomas C. Seoh as President and CEO. Mr. Seoh succeeds G. Alexander (“Zan”) Fleming, M.D., Kinexum founder, who becomes Executive Chairman and will continue to serve as a strategic advisor to Kinexum clients.
Thomas Seoh commented, “I am excited and honored to take on the Kinexum mission and lead the firm’s remarkable team of life science professionals, all of whom have decades of experience within the FDA, industry and/or academia. Kinexum views its role as more than just a source of expert advice and high-value technical and scientific services. We also strive to be trusted members of the high-performance team tasked with achieving important corporate milestones. I very much look forward to working with Zan and the multinational Kinexum faculty, who are all driven to foster innovation and accelerate the delivery of novel medical products to patients around the globe.”
"With Thomas's diverse experience in the life science industry and his expertise in corporate development and strategy, Thomas is singularly qualified to lead Kinexum. It is a major milestone for Kinexum to have someone as talented and distinguished as Thomas take the helm. "
Mr. Seoh is a life science executive and entrepreneur who has held senior leadership positions in public and private pharmaceutical, biotech and medical device companies for over 25 years. Mr. Seoh served in legal management positions with Viratek and Guilford Pharmaceuticals prior to rising to be Guilford’s SVP for Corporate and Commercial Development and CEO of neurology-focused Faust Pharmaceuticals in Strasbourg, France. He has also been involved with development of medical devices for liver dialysis, mechanical thrombectomy, and advanced wound care, He has served as a member of the Hopkins Alliance, an industry-faculty advisory board at Johns Hopkins School of Medicine. Mr. Seoh holds an A.B. in Philosophy and History and a J.D. from Harvard University.
Dr. Fleming added: “With Thomas’s diverse experience in the life science industry and his expertise in corporate development and strategy, Thomas is singularly qualified to lead Kinexum. Thomas and I share a keen interest in corporate development and the building of high-performance organizations. Over the last several months, Thomas has already made enormous contributions to Kinexum in a stem-to-stern review and institution of a strategic design process. It is a major milestone for Kinexum to have someone as talented and distinguished as Thomas take the helm. He will ensure that Kinexum serves its clients increasing well for years to come. I look forward to having more time to engage with our project teams and advocate process innovation in the translation of life science products from research through development to commercialization.”
See more: CLICK HERE
About Kinexum LLC
Kinexum LLC is an acclaimed resource for supporting the strategic, technical, and operational needs of small and large life science companies. From its original expertise in the development of small molecules for metabolic diseases, the firm has expanded its capabilities across multiple therapeutic areas to deliver high-value solutions for over 300 companies across the globe. Kinexum has expertise in the domains of small molecules, biologics, diagnostics and medical devices, nutritional products, and data systems across the fields of diabetes, metabolic disorders, healthy lifespan agents, cardiovascular diseases, oncology, gastroenterology and others. Kinexum also supports initiatives to support innovation in addressing major healthcare challenges. For more information, please visit the Kinexum website at www.kinexum.com.
Please also join us at the inaugural World Congress on Targeting Metabesity in London, October 30-31, 2017, http://metabesity2017.com/.
President and Chief Executive Officer
Chief Operating Officer